Back to search results

Observational Study on Opioid Withdrawal and Cravings

This study is looking at how wearable devices can help us understand opioid withdrawal and cravings. If you are between 18 and 50 years old, speak English, and have a history of opioid dependence, you might be able to join. You would wear an EmbracePlus Smartwatch and a Corti Sensor for 14 days during inpatient detoxification treatment. These devices will continuously collect data like heart rate, skin temperature, and cortisol levels. Researchers will compare this data with your daily scores on questionnaires about opioid withdrawal (SOWS-Gossop, COWS) and cravings (OC-VAS). The goal is to see if these devices can accurately measure changes in your body during withdrawal and cravings.

Study design
This is an observational study involving 20 participants. It is not testing a new drug, but rather how wearable sensors can detect changes in your body.
What's involved
You would wear an EmbracePlus Smartwatch and a Corti Sensor continuously for 14 days during inpatient detoxification treatment. You will also complete daily questionnaires about withdrawal and cravings.
Compensation
Not stated in the trial record.
Follow-up
Your withdrawal and craving levels will be measured daily throughout the 14-day inpatient detoxification treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06487533

Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder

Recruiting
Not specifiedAges 18–50Observational
Spark Biomedical, Inc.
~20 participants
Updated 2026-06-02 on ClinicalTrials.gov
What's tested:EmbracePlus SmartwatchCorti Sensor

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Short Opioid Withdrawal Scale Gossop (SOWS-Gossop)
Measured over Daily throughout the 14-day inpatient detoxification treatment
+3 more outcomes measured

Conditions

Opioid Withdrawal
Opioid Use Disorder

Explore related trials

Opioid Use DisorderOpioid withdrawal

Where it's being run

2 sites across 2 states
Minnesota1
Ohio1

Study leadership

  • Navid Khodaparast, PhD · PRINCIPAL_INVESTIGATOR · Chief Science Officer
  • Melanie McWade, PhD · STUDY_DIRECTOR · Senior Director of Clinical Operations
  • Carlos Tirado, MD · STUDY_CHAIR · Medical Monitor

Who to contact

Caroline Benner
[email protected]
(210) 624-8046
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Short Opioid Withdrawal Scale Gossop (SOWS-Gossop)Daily throughout the 14-day inpatient detoxification treatment

    Correlation of opioid withdrawal symptoms, as measured by the SOWS-Gossop, over time with biomarkers using the EmbracePlus Smartwatch and Corti Wearable.

  • Clinical Opioid Withdrawal Scale (COWS)Daily throughout the 14-day inpatient detoxification treatment

    Correlation of opioid withdrawal symptoms, as measured by the COWS, over time with biomarkers using the EmbracePlus Smartwatch and Corti Wearable.

  • Opioid Craving Visual Analog Scale (OC-VAS)Daily throughout the 14-day inpatient detoxification treatment

    Correlation of the intensity of opioid cravings, as measured by the OC-VAS, over time with biomarkers using the EmbracePlus Smartwatch and Corti Wearable.

  • Adverse EventsDaily throughout the 14-day inpatient detoxification treatment

    The primary safety endpoint will be the proportion of participants who experience one or more adverse events.